The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was triggered when Arrowhead ...

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

The US Food and Drug Administration (FDA) issued a press release late Friday announcing an investigation into the death of an ...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR) Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics ( NASDAQ: SRPT ).

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

Sarepta Therapeutics stock was sliding again on Monday, as investors struggled to make sense of further bad news concerning ...

Amazon (NASDAQ: AMZN) stock rose 0.7% after Jefferies stated that the impact of sweeping U.S. tariffs on the e-commerce giant appear to be "overstated for now," as it remains a "go-to destination" for ...

Retail sentiment around Sarepta Therapeutics remained upbeat on Monday after the company said Friday that the death of an ...

The FDA is investigating the death last month of an eight-year-old boy in Brazil who had received Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl)—though the company and its ...